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Abstract
Background: Invasive fungal infections, such as candidemia, caused by Candida species have been
increasing. Candidemia is not only associated with a high mortality (30% to 40%) but also extends
the length of hospital stay and increases the costs of medical care. Sepsis caused by Candida species
is clinically indistinguishable from bacterial infections. Although, the clinical presentations of the
patients with candidemia caused by Candida albicans and non-albicans Candida species (NAC) are
indistinguishable, the susceptibilities to antifungal agents of these species are different. In this study,
we attempted to identify the risk factors for candidemia caused by C. albicans and NAC in the hope
that this may guide initial empiric therapy.
Methods: A retrospective chart review was conducted during 1996 to 1999 at the Veterans
General Hospital-Taipei.
Results: There were 130 fatal cases of candidemia, including 68 patients with C. albicans and 62
with NAC. Candidemia was the most likely cause of death in 55 of the 130 patients (42.3 %). There
was no significant difference in the distribution of Candida  species between those died of
candidemia and those died of underlying conditions. Patients who had one of the following
conditions were more likely to have C. albicans, age  65 years, immunosuppression accounted to
prior use of steroids, leukocytosis, in the intensive care unit (ICU), and intravascular and urinary
catheters. Patients who had undergone cancer chemotherapy often appeared less critically ill and
were more likely to have NAC.
Conclusion:  Clinical and epidemiological differences in the risk factors between candidemia
caused by C. albicans and NAC may provide helpful clues to initiate empiric therapy for patients
infected with C. albicans versus NAC.
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Background
Invasive fungal infections caused by Candida species have
increased significantly. They now rank fourth as the most
common cause of nosocomial bloodstream infections in
the United Stated [1] and the most common one at one
major hospital in Taiwan [2]. Candidemia is not only
associated with a mortality of about 30% to 40% but also
extends the duration of hospital stay [3,4] and increases
the cost for medical care [5]. In recent years, Candida spe-
cies associated with candidemia have shifted from Cand-
ida albicans to non-albicans Candida species (NAC) [6].
Approximately half of the reported cases of candidemia
are now caused by NAC [7-10].
Patients with candidemia usually present an acute septic
syndrome that is indistinguishable from bacteremia, but
they may also exhibit a more indolent course manifested
by fever of unknown origin. Major risk factors for candi-
demia include intravascular catheters, parenteral hyperal-
imentation, and broad-spectrum antibiotics. Empirical
antifungal agents may be administrated to patients mani-
fested with fever of unknown origin and have above men-
tioned risk factors, particularly those who have been
treated with broad-spectrum antibiotics. The clinical pres-
entation of the patients with sepsis caused by C. albicans
and NAC are indistinguishable. However, NAC are often
less susceptible to fluconazole than C. albicans is [7,11,12]
and may require greater dosage to cure clinically [13,14].
We have conducted a retrospective chart review of patients
whose death was associated with candidemia. The goal
was to assist decisions to select the most appropriate
empirical therapy for patients suspected to have candi-
demia. The objective was to determine whether specific
risk factors could be identified to help selecting those
patients who are more likely infected with C. albicans ver-
sus NAC.
Methods
This study was conducted at the Veterans General Hospi-
tal-Taipei. This is a 2800-bed teaching hospital with about
69,000 admissions annually [7]. A total of 415 blood iso-
lates of Candida species (one strain per species per patient)
were collected from April 1996 to December 1999. Dur-
ing this period 130 patients met the inclusion criteria of
having at least one positive blood culture for Candida spe-
cies within one month prior to the fatal outcome. There
were 68 patients infected with C. albicans and 62 with
NAC.
Candida species were isolated from blood using BACTEC
860 system (Becton Dickinson, INC, Sparks, MD). The
species were identified using API-32C system (bioMerieux
Vitek, Inc, St. Louis, MI).
Clinical data
Clinical data of 130 patients were recorded on standard-
ized forms and analyzed according to age at the time of
diagnosis, gender and underlying illnesses. These
included cancer, diabetes, immunosuppression
accounted to prior use of steroids, systemic antifungal
agents, cancer chemotherapy, parenteral nutrition, the
presence of central or arterial line, endotracheal tube, and
urinary catheter, admission to an intensive care unit
(ICU), history of infection or gastrointestinal surgery,
hemogram, antifungal management, and cause of death.
The predisposing events within one month prior to diag-
nosis and the laboratory data within seven days prior to
obtaining the first positive blood culture were analyzed.
To decide that a patient died directly of candidemia or
underlying illness, we recoded the causes of death accord-
ing to the death certificate of the patients.
Statistical analysis
The statistical significance of association between categor-
ical variables was assessed using the Fisher's Exact Test.
The risk factors with p values < 0.1 in the univariate anal-
ysis were placed in a multivariate analysis using the mul-
tiple logistic regression package in the SAS System for
Windows V8. Confidence limit of 95% means that the
confidence limit contains the true value of odds ratio with
probability of 0.95. The narrower the confidence limit is,
the more accurate the estimate is.
Results
The population consisted of 130 patients whose death
was associated with candidemia. Fifty-five (42.3 %) of
these deaths were considered to be directly caused by Can-
dida species. The remaining died of complications of their
underlying illness. The distribution of species of the total
deaths and those causally related to candidemia is shown
in Table 1. There were no significant differences in causa-
tion of death according to species. Interestingly, of the
four major species related to candidemia, 61.5% of the
isolated  Candida glabrata contributed to mortality, fol-
lowed by 50% of Candida parapsilosis, 41.2% of C. albicans,
and 31.3% of Candida tropicalis.
The demographic and clinical characteristics of the study
population categorized according to the presence of C.
albicans or NAC in the blood are summarized in Table 2.
The significant (p ≤  0.05) risk factors on univariate analy-
sis for C. albicans candidemia were age  65 years, prior
bacterial urinary tract infection, central venous catheter,
parenteral nutrition and leucocytosis with white blood
cell counts (WBC)  15000/mm3, without significant
neutropenia with absolute neutrophil counts (ANC) 
100000/mm3. The significant risk factors for NAC were
age < 65 years, cancer chemotherapy, neutropenia (WBC
< 3000/mm3) and severe thrombocytopenia (plateletBMC Infectious Diseases 2005, 5:22 http://www.biomedcentral.com/1471-2334/5/22
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count  20000 /mm3). NAC patients were more likely to
have cancers and to be located on the medical wards (p =
0.08). When multivariate analysis was employed, the sig-
nificant risk factors for C. albicans were age  65 years,
immunosuppressive therapy, and leucocytosis. Signifi-
cant risk factors for NAC were age < 65 years and location
on medical wards, which are shown in Table 3.
Discussion
Candida albicans remains the most common species caus-
ing candidemia, but the proportion caused by NAC is
Table 1: Distribution of Candida species of fatal outcome attributed to disseminated candidemia
Blood isolates (N = 130) Death directly related to candidemia (N = 55)
species % in Number 130 isolates % in Number 55 isolates % in species of blood isolates
C. albicans 68 52.3 28 50.9 41.2
non-albicans Candida species 62 47.7 27 49.1 43.5
C. tropicalis 32 24.7 10 18.2 31.3
C. glabrata 13 10.0 8 14.5 61.5
C. parapsilosis 12 9.2 6 10.9 50.0
C. guilliermondii 2 1.5 1 1.8 50.0
C. peniculosa 2 1.5 2 3.6 100.0
C. famata 1 0.8 0 0 0
Table 2: Characteristics of 130 patients who died in association with candidemia
Characteristic C. albicans (N = 68) NAC (N = 62) Fisher's Exact Test
No. % No. % Two-sided P-value
Age  65 years old 56 82.4 36 58.1 0.004*
MICU 6 8.8 10 16.1 0.286
Medical ward stay 24 35.3 32 51.6 0.077*
Cancer 24 35.3 32 51.6 0.077*
Immunosuppressive therapy 17 25 7 11.3 0.069*
Bacteremia 25 36.8 15 24.2 0.133
Bacterial urinary tract infection 23 33.8 10 16.1 0.026*
Prior antifungal administration 5 7.4 9 14.5 0.259
Catheters within 30 days 65 95.6 56 90.3 0.309
ETT 35 51.5 23 37.1 0.114
CVC 57 83.8 41 66.1 0.025*
AL 21 30.9 14 22.6 0.326
Urinary catheter 49 72.1 39 62.9 0.348
PPN 50 73.5 34 54.8 0.029*
Cancer chemotherapy 5 7.4 12 19.4 0.066*
Corticosteroids 26 38.2 18 29 0.354
ANC (N = 44) (N = 40) 1
ANC  1500/mm3 24 . 5 2 5
WBC (N = 67) (N = 61) 0.0004*
 3000/mm3 46 1 4 2 3
3000/mm3 to 5000/mm3 35 52.2 38 62.3
> 15000/mm3 28 41.8 9 14.8
Platelet (N = 66) (N = 61) 0.011*
 20000/mm3 5 7.6 10 16.4
20000/mm3 to 100000/mm3 20 30.3 29 47.5
> 100000/mm3 41 62.1 22 36.1
* Factors selected for multivariate analysis. AL, arterial line; ANC, absolute neutrophil count; CVC, central venous catheter; ETT, endo trachial 
tube; ICU, Intensive care unit; PN, parenteral nutrition; WBC, white blood cellBMC Infectious Diseases 2005, 5:22 http://www.biomedcentral.com/1471-2334/5/22
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increasing [7-10]. Patients with NAC are more likely to
require greater dosage of fluconazole to cure clinically
[13,14]. Thus there is a need to identify patients at risk of
NAC candidemia to initiate empirical amphotericin B
therapy or high-dose fluconazole.
Krcmery and Barnes have identified the following risk fac-
tors for NAC [15]. These include prophylaxis with azole
compounds as a risk factor for C. krusei and C. glabrata,
neutropenia and bone marrow transplantation for C. trop-
icalis, and insertion of foreign bodies, neonates, and
hyperalimentation for C. parapsilosis [15-18]. In this study
we have identified additional risk factors that help distin-
guish candidemia caused by C. albicans and NAC. The
most important risk factors for C. albicans are the old age,
procedures associated with intensive care, and an acute
sepsis. The most important risk factors for NAC are cancer
chemotherapy in association with leukopenia and
thrombocytopenia.
It has been reported that Candida species exhibit a spec-
trum in the extent of adherence to tissues, which corre-
lates with the pathogenicity in humans and animals [19].
Candida albicans exhibit the greatest capacity to adhere to
gingival epithelial cells, followed by C. tropicalis and C.
glabrata [19]. The capacity of yeasts to attach to a wide
range inanimate surfaces appears to protect them from
immune responses and antimicrobial agents [20]. This
may explain why C. albicans is more likely to be associated
with central venous catheters in this study.
Conventional methods to eradicate C. albicans rely upon
the use of antifungal drugs designed to kill the yeast or
arrest its growth. However, removal of intravascular cath-
eters is in fact the most simple and effective method
[21,22]. Another approach is to design new agents that
disrupt adherence of the yeasts to host tissues and
catheters.
Conclusion
It is customary to administer amphotericin B for critically
ill patients suspected of having candidemia. More often
than not, azoles are used for relatively stable patients.
NAC tend to be less susceptible to fluconazole than C.
albicans is [7,11,23]. Thus, greater dosage is needed till the
causative microorganism is isolated and identified, partic-
ularly with patients at high risk for NAC candidemia.
Though, a large, prospective study is needed to validate
this concept, the risk factors identified in this study may
help, in clinical practice, to differentiate fatal candidemia
caused by C. albicans versus NAC.
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